Molecular approaches to the diagnosis of sporadic and nevoid basal cell carcinoma syndrome-associated odontogenic keratocysts

Oral and Maxillofacial Surgery Clinics of North America

Volumn 15, Issue 3, 2003, Pages 447-461

  Todd, Randy ^a   August, Meredith ^a,b  

^a Salem Peabody Oral Surgery Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RISK; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; KERATINIZATION; ODONTOGENIC CYST; ODONTOGENIC KERATOCYST; REVIEW; TREATMENT PLANNING; TUMOR CLASSIFICATION;

EID: 0141737475     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1042-3699(03)00039-6     Document Type: Review

References (72)

1. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. Philadelphia: WB Saunders Co; 1995.
2. Bale AE. The nevoid basal cell carcinoma syndrome: genetics and mechanism of carcinogenesis. Cancer Invest 1997;15:180-6.
3. Woolgar JA, Rippin JW, Browne RV. A comparative histological study of odontogenic keratocysts in basal cell naevus syndrome and control patients. J Oral Pathol 1987;16:75-80.
4. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Medicine 1987;66:98-113.
5. Forssell K, Forssell H, Kahnberg KE. Recurrence of keratocysts: a long term follow-up study. Int J Oral Maxillofac Surg 1988;17:25-8.
6. Dominguez FV, Keszler A. Comparative study of keratocysts, associated and non-associated with nevoid basal cell carcinoma syndrome. J Oral Pathol 1988;17: 39-42.
7. Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Am J Med Genet 1997;69: 299-308.
8. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993;30:460-4.
9. Hodgkinson DJ, Woods JE, Dahlin DC, Tolman DE. Keratocysts of the jaw: clinicopathologic study of 79 patients. Cancer 1978;4:803-13.
10. Donatsky O, Hjorting-Hansen E. Recurrence of the odontogenic keratocyst in 13 patients with the nevoid basal cell carcinoma syndrome: a 6-year follow-up. Int J Oral Surg 1980;9:173-9.
11. El Sobky RA. Successful treatment of an intractable case of hereditary basal cell carcinoma syndrome with paclitaxel. Arch Dermatol 2001;137:827-8.
12. Sidransky D. Emerging molecular markers of cancer. Nature Rev CA 2002;2:210-9.
13. Ahlfors E, Larsson A, Sjogren S. The odontogenic OKC: a benign cystic tumor? J Oral Maxillofac Surg 1984;42:10-9.
14. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part I. Clinical and early experimental evidence of aggressive behavior. Oral Oncol 2002;38:219-26.
15. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. Proliferation and genetics. Oral Oncol 2002;38:323-31.
16. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 3. Immunocytochemistry of cytokeratin and other epithelial markers. Oral Oncol 2002;38:407-15.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
18. Hahn WC, Weinberg RA. Mechanisms of disease: rules for making human tumor cells. N Engl J Med 2002; 347:1593-602.
19. Barreto DC. New considerations about the diagnosis of odontogenic keratocysts. Oral Med 2001;6:350-7.
20. Anand VK, Arrowood JP, Krolls SO. Odontogenic keratocysts: a study of 50 patients. Laryngoscope 1995; 105:14-6.
21. Rodu B, Tate AL, Martinez MG. The implications of inflammation in odontogenic keratocysts. J Oral Pathol 1987;16:518-21.
22. De Paula AMB, Carvalhais JN, Domingues MG, Barreto DC, Mesquita RA. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation. J Oral Pathol Med 2000;29:477-82.
23. Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med 2002;347:1512-20.
24. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278(5340):1054-9.
25. van Houten VMM, Tabor MP, van den Brekel MWM, et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 2000;6: 3803-16.
26. Todd R, Lingen MW, Kuo WP. Gene expression profiling using laser capture microdissection. Expert Rev Mol Diagn 2002;2:89-99.
27. Todd R, Wong DTW. DNA hybridization arrays for gene expression analysis of human oral cancer. J Dent Res 2002;81:89-97.
28. Todd R, Donoff RB, Wong DTW. The chromosome: cytogenetic analysis and its clinical application. J Oral Maxillofac Surg 2000;58:1036-41.
29. Todd R, Donoff RB, Kim Y, Wong DT. From the chromosome to DNA: RFLP analysis and its clinical applications. J Oral Maxillofac Surg 2001;59:660-7.
30. Kim Y, Flynn TR, Donoff RB, Wong DT, Todd R. The gene: the polymerase chain reaction (PCR) and its clinical application. J Oral Maxillofac Surg 2002;60: 808-15.
31. Kim Y, Donoff RB, Wong DT, Todd R. The nucleotide: DNA sequencing and its clinical application. J Oral Maxillofac Surg 2002;60:924-30.
32. Cohen MMJ. Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses. Int J Oral Maxillofac Surg 1999;28:216-23.
33. Motoyama J, Takashi T, Takeshima K. Ptch2, a second mouse Patched gene is co-expressed with sonic hedgehog. Nat Genet 1998;18:104-6.
34. Zedan W, Robinson PA, High AS. A novel polymorphism in the PTC gene allows easy identification of allelic loss in basal cell nevus syndrome lesions. Diagn Mol Pathol 2001;10:41-5.
35. Todd R, Margolin DH. Challenges of single-cell diagnostics: analysis of gene expression. Trends Mol Med 2002;8:354-7.
36. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressmann C. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14: 78-81.
37. Unden AR, Backdahl MS, Holmberg E, Larsson C, Toftgard R. Fine mapping of the locus for nevoid basal cell carcinoma syndrome on chromosome 9q. Acta Derm Venereol 1997;77:4-9.
38. Nagano T, Bito T, Kallassy M, Nakazawa H, Ichihashi M, Ueda M. Overexpression of the human homologue of Drosophila patched (PTCH) in skin tumours: specificity for basal cell carcinoma. Br J Dermatol 1999; 140:287-90.
39. Zedan W, Robinson PA, Markham AF, High AS. Expression of the sonic hedgehog receptor PATCHED in basal cell carcinomas and odontogenic keratocyts. J Pathol 2001;194:473-7.
40. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001; 286:1271-8.
41. Celis JE, Kruhoffer M, Gromova I, et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 2000;480:2-16.
42. Pavelic B, Levant S, Crinc I, et al. PTCH gene altered in dentigerous cysts. J Oral Pathol Med 2001;30:569-76.
43. Barreto DC, Bale AE, De Marco L, Gomez RS. Immunolocalization of PTCH protein in odontogenic cysts and tumors. J Dent Res 2002;81:757-60.
44. Levanat S, Pavelic B, Crinc I, Oreskovic S, Manojiovic S. Involvement of PTCH gene in various noninflammatory cysts. J Mol Med 2000;78:140-6.
45. Ogden GR, Chisholm DM, Kiddie RA, Lane DP. p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. J Clin Pathol 1992;45: 1007-10.
46. Li TJ, Browne RM, Matthews JB. Epithelial cell proliferation in odontogenic keratocysts: immunocytochemical study of Ki67 in simple, recurrent and basal cell naevus syndrome (BCNS)-associated lesions. J Oral Pathol Med 1995;24:221-6.
47. Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 1995;24:393-7.
48. Lo Muzio L, Staibano S, Pannone G, et al. Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome. J Dent Res 1999;78:1345-53.
49. Li TJ, Browne RM, Prime SS, Paterson IC, Matthews JB. p53 expression in odontogenic keratocyst epithelium. J Oral Pathol Med 1996;25:245-55.
50. Li TJ, Browne RM, Matthews JB. Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. J Oral Pathol Med 1994;23:184-9.
51. el Murtadi A, Grehan D, Toner M, McCartan BE. Proliferating cell nuclear antigen staining in syndrome and nonsyndrome odontogenic keratocysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81: 217-21.
52. Piatelli A, Fioroni M, Santinelli A, Rubini C. Expression of proliferating cell nuclear antigen in ameloblastomas and odontogenic cysts. Oral Oncol 1998;34: 408-12.
53. Takahashi H, Fujita S, Yamabe S, et al. Comparison of proliferating cell nuclear antigen expression in odontogenic keratocyst and ameloblastoma: an immunohistochemical study. Anal Cell Pathol 1998;16: 185-91.
54. Nakamura N, Mitsuyasu T, Mitsuyasu Y, Taketomi T, Higuchi Y, Ohishi M. Marsupialization for odontogenic keratocysts: long-term follow-up analysis of the effects and changes in growth characteristics. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:543-9.
55. Matthews JB, Mason GI, Browne RM. Epithelial cell markers and proliferating cells in odontogenic jaw cysts. J Pathol 1988;156:283-9.
56. Crowley TE, Kaugars GE, Gunsolley JC. Odontogenic keratocysts: a clinical and histologic comparison of the parakeratin and orthokeratin variants. J Oral Maxillofac Surg 1992;50:22-31.
57. High AS, Robinson PA, Klein CE. Discrimination of para-keratinized odontogenic keratocysts from other odontogenic and non-odontogenic cyst types by expression of a 380kd cell-surface glycoprotein. J Oral Pathol Med 1993;22:363-7.
58. Howell RE, Handlers JP, Aberle AM, Abrams AM, Melrose RJ. CEA immunoreactivity in odontogenic tumors and keratocysts. Oral Surg Oral Med Oral Pathol 1988;66:576-80.
59. Maeda Y, Hirota J, Yoneda K, Osaki T. Immunohistochemical study of jaw cysts: different existence of keratins in odontogenic and non-odontogenic epithelial linings. J Oral Pathol Med 1990;19:289-95.
60. Gordeeff M, Clergeau-Guerithault S. Expression of certain cytokeratins in the epithelium of dentigerous and primordial cyst. J Biol Buccale 1990;18:59-63.
61. MacDonald AW, Fletcher A. Expression of cytokeratin in the epithelium of dentigerous cysts and odontogenic keratocysts: an aid to diagnosis. J Clin Pathol 1989;42: 736-41.
62. Smith AJ, Matthews JB. Odontogenic epithelium and its residues. In: Browne RM, editor. Investigative pathology of the odontogenic cysts. Boca Raton (FL): CRC Press; 1991. p. 53-85.
63. Meara JG, Pilch BZ, Shah SS, Cunningham MJ. Cytokeratin expression in the odontogenic keratocyst. J Oral Maxillofac Surg 2000;58:862-5.
64. August M, Faquin WC, Troulis M, Kahan LB. Differentiation of odontogenic keratocysts from nonkeratinizing cysts by use of fine-needle aspiration biopsy and cytokeratin-10 staining. J Oral Maxillofac Surg 2000; 58:935-40.
65. August M, Faquin WC, Ferraro N, Kahan L. Fine needle aspiration biopsy of intraosseous jaw lesions. J Oral Maxillofac Surg 2000;57:731-8.
66. August M, Faquin WC, Troulis M, Kahan L. Dedifferentiation of odontogenic keratocyst epithelium as reflected by changes in cytokeratin 10 expression: implications for management. J Oral Maxillofac Surg 2003; 61:678-83.
67. Marker P, Brondum N, Clausen PP, Bastian HL. Treatment of large odontogenic keratocysts by decompression and later cystectomy: a long-term follow-up and a histologic study of 23 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:122-7.
68. Brondum N, Jensen VJ. Recurrence of keratocysts and decompression treatment. A long-term follow-up of forty-four cases. Oral Surg Oral Med Oral Pathol 1991;72:265-9.
69. Toller PA. Protein substances in odontogenic cyst fluids. Br Dent J 1970;128:317-22.
70. Smith G, Smith AJ, Browne RM. Analysis of odontogenic cyst fluid aspirates. IRCS Med Sci 1986;14:304.
71. Douglas CWI, Craig GT. Quantitation of lactoferrin in odontogenic cyst fluids. J Clin Pathol 1989;42:180-3.
72. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations smoothed and patched can be reversed by cyclopomine. Nature 2000;406:1005-9.